Dizal's Sunvozertinib Receives Breakthrough Therapy Designation for First-Line NSCLC Treatment
Dizal, a biopharmaceutical company dedicated to the development of novel treatments for cancer and immunological diseases, has announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for sunvozertinib. This designation is for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), who have not received prior systemic therapies. Publish Date: 13-10-2024 Source: Dizal Pharma Advanced metastatic NSCLC has shown a significant increase in survival rates with chemotherapy compared to best supportive care alone. Subsequent advancements included improved response rates with third-generation agents such as paclitaxel, docetaxel, vinorelbine, and gemcitabine, surpassing the efficacy of second-generation treatments like ifosfamide, ...